Cost-effectiveness of adjuvant alectinib in the treatment of patients with resected stage IB-IIIA ALK-positive non-small lung cancer in France, based on the ALINA study
{{output}}
Background and objective: Alectinib has demonstrated significant disease-free survival (DFS) benefits as adjuvant therapy for resected stage IB-IIIA ALK-positive non-small-cell lung cancer (NSCLC) in the ALINA study. This study a... ...
